Literature DB >> 11972711

Host-vs.-altered-host eruptions in patients on liposomal doxorubicin.

Henry Skelton1, Jill Linstrum, Kathleen Smith.   

Abstract

BACKGROUND: Anthracycline antitumor antibiotics are the most commonly used chemotherapeutic agents. One of these is doxorubicin. Liposomal doxorubicin was developed as a drug delivery system in order to deliver the active drug intracellularly while decreasing the systemic toxicity, particularly hematological and cardiac toxicity.
METHODS: The clinical and histologic findings of the cutaneous eruptions of associated with liposomal doxorubicin are reviewed.
RESULTS: The eruptions occurred in three women with metastatic ovarian carcinoma who were treated with liposomal doxorubicin. These three patients developed erythematous macular/papular to plaque cutaneous lesions, and in one patient a vesicular component. The eruptions involved the trunk and extremities approximately 3-4 weeks after completions of therapy. None of the patients had any documented infections, and none of the patients had symptoms other than pruritus. The eruptions cleared over a period of weeks to months. Histologic features included an interface dermatitis with numerous apoptotic/dyskeratotic cells within the epidermis, with involvement the intra-epidermal sweat ducts and the infundibulum of hair follicles.
CONCLUSION: We believe that these eruptions represented a chemotherapy induced host-vs.-altered host reaction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11972711     DOI: 10.1034/j.1600-0560.2002.290304.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  3 in total

1.  Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literature.

Authors:  Joanna Kubicka-Wołkowska; Magdalena Kędzierska; Maja Lisik-Habib; Piotr Potemski
Journal:  Oncol Lett       Date:  2016-10-24       Impact factor: 2.967

2.  CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukemia-A case report.

Authors:  Ruth M Urbantat; Valentin Popper; Elisabeth Menschel; Michael Pfeilstöcker; Ernst Forjan; Alexander Nader; Catherine R Sieghart; Felix Keil; Elisabeth Koller
Journal:  Clin Case Rep       Date:  2021-02-12

3.  High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study.

Authors:  Yanfang Zhao; Wenjia Su; Guohua Liang; Xiaoyu Shan; Weiwei Ma; Dabei Tang; Liru Li; Xingjian Niu; Shu Zhao; Qingyuan Zhang; Wenhui Zhao
Journal:  BMC Pharmacol Toxicol       Date:  2021-10-25       Impact factor: 2.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.